Gothenburg stem cell company Cellartis announced on Thursday that it is to be acquired by French biotech company Cellectis.
Cellartis was founded ten years ago in Gothenburg as a university spin-off. It has developed a world-leading stem cell platform and products based on human pluripotent stem cells.
The acquisition will see the stem cell innovation from Cellartis merge with world leading genome engineering capabilities from Cellectis.
- We are enthusiastic to have the opportunity to combine Cellartis' world-renowned expertise in pluripotent stem cells-based industrial applications with Cellectis' highend genetic engineering platform. Together, we will be in a position to accelerate the development of stem cell based solutions including therapies targeting diseases reputed as incurable thanks to regenerative medicine, says Gunnar Fernström, Chairman of Cellartis in a statement.
In return for the full divestment of their stake, Cellartis shareholders will receive 16.4 million euro in cash and 1.93 million Cellectis shares.
